Xultophy 100/3.6 Flexpen Injection 100Iu (1 Box = 1 Injection)

Name: Xultophy 100/3.6 Flexpen Injection 100Iu (1 Box = 1 Injection)
Brand: NOVO NORDISK PAKISTAN LTD
Price: 9156

Brand : novo nordisk pakistan ltd

Rs. 9,156.00

|

QUICK DELIVERY

Xultophy 100/3.6 Specification

Requires Prescription (YES/NO)

Yes

Generics

Insulin degludec + Liraglutide

Used For

Diabetes Management

How it works

XULTOPHY 100/3.6 is a combination product consisting of insulin degludec and liraglutide. Insulin degludec : The primary activity of insulin degludec is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis. Liraglutide : Liraglutide is a GLP-1 receptor agonist that increases glucosedependent insulin release, decreases glucagon secretion, and slows gastric emptying .

Xultophy 100/3.6 Usage And Safety

Dosage

Insulin degludec + Liraglutide

Side Effects

Hypoglycaemia , nausea , diarrhoea , vomiting , constipation , dyspepsia , gastritis , abdominal pain , GERD , abdominal distension , inj-site reaction .

Drug Interactions

Pioglitazone (discontinue). MAOIs , beta-blockers , ACE inhibitors , salicylates , anabolic steroids , sulfonamides . Oral contraceptives , thiazides , glucocorticoids , thyroid hormones , sympathomimetics , growth hormones , danazol , octreotide . Lanreotide.

Indication

Xultophy 100/3.6 (insulin degludec and liraglutide) injection 100 units/mL and 3.6 mg/mL is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

When not to Use

Patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 . During episodes of hypoglycemia . Patients with a serious hypersensitivity reaction to insulin degludec, liraglutide, or any of the excipients in XULTOPHY 100/3.6 .

Xultophy 100/3.6 Precautions

Precaution

Never Share a Xultophy 100/3.6 Pen Between Patients, even if the needle is changed. Sharing of the pen poses a risk for transmission of blood-borne pathogens.

Xultophy 100/3.6 Warnings

Warning 1

Instruct patients to check the label before each injection since accidental mix-ups with insulin containing products can occur. Do not administer more than 50 units of Xultophy 100/3.6 daily. Do not exceed the 1.8 mg maximum recommended dose of liraglutide or use with other GLP-1 RAs.

Warning 2

Acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis, have been reported postmarketing for liraglutide, usually in association with nausea, vomiting, diarrhea, or dehydration. Advise patients of the potential risk of dehydration due to gastrointestinal adverse reactions and take precautions to avoid fluid depletion.

Warning 3

All insulin containing products, including Xultophy 100/3.6 can lead to life-threatening hypokalemia, which may then cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.